Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ March 5, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics. The Phase I ... Read More

FOR IMMEDIATE RELEASE Covington, KY – 22 February 2019 Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business Courier at the 2019 Healthcare Hero Awards Celebration. These annual awards honor individuals and organizations that have improved the ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ 19 November 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster review and a second case study poster were presented at the Society of Neuro-Oncology (SNO) Annual Meeting held November 16-18 in New ... Read More

National Cancer Institute (NCI) Selects Bexion as a Presenting Company FOR IMMEDIATE RELEASE [Covington, KY ~ October 18, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announces that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15th Annual BioNetwork Partnering Summit, held ... Read More

CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 Sometimes things come full circle. Fourteen years ago, CancerFree KIDS awarded its very first research grant to a young investigator at Cincinnati Children’s Hospital Medical Center (CCHMC) to study a long shot idea that no one ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting Poster Session, held in ... Read More

FOR IMMEDIATE RELEASE Covington, KY ~ May 22,2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature one clinical poster presentation and three online publications at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1-5 in Chicago, IL. The ... Read More

FOR IMMEDIATE RELEASE Covington, KY April 16, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today that the four abstracts submitted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago, Illinois have all been accepted. One of the accepted presentations ... Read More